A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

被引:7
|
作者
Xie, Peiling [1 ]
An, Rui [2 ]
Yu, Shibo [1 ]
He, Jianjun [1 ]
Zhang, Huimin [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Breast Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Hepatol Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; ER+/PR-/HER2-; Immune classification; Multi-omics; PROGESTERONE-RECEPTOR EXPRESSION; PREDICTIVE-VALUE; PD-1; BLOCKADE; CROSS-TALK; ESTROGEN; TAMOXIFEN; GROWTH; TUMORS; IMMUNOTHERAPY; MECHANISMS;
D O I
10.1186/s12967-021-03076-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The diversity and plasticity behind ER+/PR-/HER2- breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. Methods: Based on the immune-related gene expression profiles of 411 ER+/PR-/HER2- breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. Results: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-gamma response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. Conclusion: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, also provided important implications for clinical translations.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
    Fjermeros, Kamilla
    Ghannoum, Salim
    Geisler, Stephanie B.
    Bhargava, Sameer
    Tahiri, Andliena
    Klajic, Jovana
    Luders, Torben
    Fongard, Marie
    Nawaz, Meh Sameen
    Bosnjak-Olsen, Tatjana
    Buvarp, Unn-Cathrin Edvardsen
    Johanna Rosenskiold, Aino Katri
    Nguyen, Nam Thi
    Sletbak, Tone Tysko
    Seyedzadeh, Manouchehr
    Selsas, Knut
    Porojnicu, Alina Carmen
    Skjerven, Helle Kristine
    Hovda, Tone
    Sahlberg, Kristine Kleivi
    Torland, Lilly Anne
    Lyngra, Marianne
    Hammarstrom, Clara Louise
    Honigsperger, Elma Bahonjic
    Noone, John Christopher
    Mathiassen, Silje
    Hurtado, Antoni
    Goel, Shom
    Koff, Andrew
    Tekpli, Xavier
    Kristensen, Vessela N.
    Geisler, Juergen
    FUTURE ONCOLOGY, 2024,
  • [42] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [43] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Xinming Song
    Pintian Wang
    Ruiling Feng
    Mandika Chetry
    E. Li
    Xiaohua Wu
    Zewa Liu
    Shasha Liao
    Jing Lin
    Clinical and Translational Oncology, 2024, 26 : 389 - 397
  • [44] Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
    Varella, Leticia
    Cristofanilli, Massimo
    ONCOTARGETS AND THERAPY, 2023, 16 : 189 - 196
  • [45] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Perez, Edith A.
    Patel, Tejal
    Moreno-Aspitia, Alvaro
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (02) : 261 - 271
  • [46] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Song, Xinming
    Wang, Pintian
    Feng, Ruiling
    Chetry, Mandika
    Li, E.
    Wu, Xiaohua
    Liu, Zewa
    Liao, Shasha
    Lin, Jing
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 389 - 397
  • [47] Clinical implications of molecular heterogeneity in highly proliferative, ER-positive, HER2-negative breast cancer
    Bianchini, G.
    Pusztai, L.
    Kelly, C. M.
    Iwamoto, T.
    Callari, M.
    Symmans, W. F.
    Gianni, L.
    CANCER RESEARCH, 2012, 72
  • [48] Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Edith A. Perez
    Tejal Patel
    Alvaro Moreno-Aspitia
    Breast Cancer Research and Treatment, 2010, 121 : 261 - 271
  • [49] Effective sequence of endocrine therapy for ER-positive and HER2-negative metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Tashima, Rumiko
    Fujisue, Mamiko
    Nakano, Masahiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] The challenging ER-negative/PR-negative/HER2-negative patient; a promising candidate for EGFR targeted therapy?
    Siziopikou, KP
    Ariga, R
    Proussaloglou, KE
    Forbes, D
    Valadez, C
    Gattuso, P
    Cobleigh, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S24 - S24